Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;160(1):322-332.
doi: 10.1016/j.ygyno.2020.10.017. Epub 2020 Nov 5.

Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies

Elizabeth K Lee  1 , Amanda N Fader  2 , Alessandro D Santin  3 , Joyce F Liu  4
Affiliations
Review

Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies

Elizabeth K Lee et al. Gynecol Oncol. 2021 Jan.

Abstract

Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer. Multimodality treatment with surgery, radiotherapy, and chemotherapy is commonly used, given its propensity for extrauterine spread, distant recurrences, and poor prognosis. However, the use of molecularly-based therapy is expanding. Here, we review key molecular features of USC, discuss current management, and assess the landscape of novel therapies and combinations.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Santin reports grants from PUMA, grants from IMMUNOMEDICS, grants from GILEAD, grants from SYNTHON, grants from MERCK, grants from BOEHINGER-INGELHEIM, grants from GENENTECH, grants from TESARO, during the conduct of the study. Dr. Liu reports advisory board participation for AstraZeneca, Clovis, Genentech, Merck, Regeneron, and Tesaro/GSK, outside the submitted work; and funding to her institution for study conduct as PI on trials from 2× Oncology, Aravive, Arch Oncology, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, CytomX Therapeutics, GlaxoSmithKline, Regeneron, Surface Oncology, Tesaro, and Vigeo Therapeutics. Dr. Fader reports personal fees from Merck, personal fees from Mersana, personal fees from Eisai, outside the submitted work. Dr. Elizabeth Lee has nothing to disclose.

MeSH terms

LinkOut - more resources